Joel Bard

1.7k citations

17 papers · 1.2k indexed · h-index 14

Hepatology top 5%
- Hepatitis C virus research 2
Molecular Biology top 10%
- Biochemical and Molecular Research 2
- PI3K/AKT/mTOR signaling in cancer 2
- RNA Research and Splicing 2
- RNA and protein synthesis mechanisms 2
Inorganic Chemistry top 10%
Biotechnology top 10%
Infectious Diseases
Genetics
- Chronic Lymphocytic Leukemia Research 2
Pharmacology
- Pharmacological Effects of Natural Compounds 2
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 2

Co-authors: Andrew Bohm Alberto Di Donato Stephen J. Lippard Matthew H. Sazinsky Dan Lü Shui-Zhong Yan Yuequan Shen Zenon Grabarek
Cited by: Hepatology Molecular Biology Inorganic Chemistry
Journals: Journal of Medicinal Chemistry (4 papers)Journal of Biological Chemistry (3 papers)Bioorganic & Medicinal Chemistry Letters (2 papers)
Partner nations: United States Canada Italy

In The Last Decade

Joel Bard

17 papers receiving 1.2k citations

Peers

Countries citing papers authored by Joel Bard

Since Specialization

Citations

This map shows the geographic impact of Joel Bard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Bard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Bard more than expected).

Fields of papers citing papers by Joel Bard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel Bard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Bard. The network helps show where Joel Bard may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Joel Bard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Joel Bard Line = papers co-authored together Joel Bard links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work
1	A Physiologically‐Based Pharmacokinetic Model for the Prediction of “Half‐Life Extension” and “Catch and Release” Monoclonal Antibody Pharmacokinetics CPT Pharmacometrics & Systems Pharmacology ·Hannah M. Jones,John Tolsma,Zhiwei Zhang,Paul Jasper,Alexandra Khristolyubova,Gregory L. Weber,Katherine Wright,Joel Bard,Robert D. Bell,Dean Messing,Kerry Kelleher,Nicole Piche‐Nicholas,Robert O. Webster	2020	12
2	A Combination of Structural and Empirical Analyses Delineates the Key Contacts Mediating Stability and Affinity Increases in an Optimized Biotherapeutic Single-chain Fv (scFv) Journal of Biological Chemistry ·Chao Tu,Virginie Terraube,Amy Tam,Wayne R. Stochaj,Brian J. Fennell,Laura Lin,Mark Stahl,Edward R. LaVallie,Will Somers,William J.J. Finlay,E. Samotoenkova,Joel Bard,Orla Cunningham	2015	18
3	Identification of pyrimidine derivatives as hSMG-1 inhibitors Bioorganic & Medicinal Chemistry Letters ·Ariamala Gopalsamy,Eric M. Bennett,Mengxiao Shi,Weiguo Zhang,Joel Bard,Ker Yu	2012	44
4	Discovery of HSD-621 as a Potential Agent for the Treatment of Type 2 Diabetes ACS Medicinal Chemistry Letters ·Zhao‐Kui Wan,Gyeong Ho Jang,Huan‐Qiu Li,Manus Ipek,Jason Xiang,Vipin Suri,Seung Hahm,Joel Bard,Kristine Svenson,Xin Xu,Xianbin Tian,Mengmeng Wang,Anis Attour,Miao Chen,Ariful Qadri,Chung-Tae Kim,Mylène Perreault,Tarek S. Mansour,James F. Tobin,Eddine Saiah	2012	11
5	Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR) Bioorganic & Medicinal Chemistry Letters ·Hwei‐Ru Tsou,Jared Ray McCoppin,Gary H. Birnberg,G Grosu,Matthew G. Bursavich,Joel Bard,Natasja Brooijmans,Lourdes Toral‐Barza,Irwin Hollander,Tarek S. Mansour,Semiramis Ayral‐Kaloustian,Ker Yu	2010	34
6	A Selective Matrix Metalloprotease 12 Inhibitor for Potential Treatment of Chronic Obstructive Pulmonary Disease (COPD): Discovery of (S)-2-(8-(Methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408) Journal of Medicinal Chemistry ·Wei Li,Jianchang Li,Lian‐Shih Fan,Junjun Wu,Rajeev Hotchandani,Kristina Cunningham,Iain J. McFadyen,Joel Bard,Paul Morgan,Franklin Schlerman,Xin Xu,Steve Tam,Samuel J. Goldman,Cara Williams,Joseph P. Sypek,Tarek S. Mansour	2009	85
7	Efficacious 11β-Hydroxysteroid Dehydrogenase Type I Inhibitors in the Diet-Induced Obesity Mouse Model Journal of Medicinal Chemistry ·Zhao‐Kui Wan,Gyeong Ho Jang,Jason Xiang,Huan‐Qiu Li,Manus Ipek,Joel Bard,Kristine Svenson,Tarek S. Mansour,Xin Xu,Xianbin Tian,Vipin Suri,Seung Hahm,Yuzhe Xing,Miao Chen,Anis Attour,Ariful Qadri,Chung-Tae Kim,Mylène Perreault,James F. Tobin,Eddine Saiah	2009	48
8	ATP-Competitive Inhibitors of the Mammalian Target of Rapamycin: Design and Synthesis of Highly Potent and Selective Pyrazolopyrimidines Journal of Medicinal Chemistry ·Arie Zask,Jeroen C. Verheijen,Kevin J. Curran,Joshua A. Kaplan,David J. Richard,Paweł Nowak,David J. Malwitz,Natasja Brooijmans,Joel Bard,Kristine Svenson,Judy Lucas,Lourdes Toral‐Barza,Weiguo Zhang,Irwin Hollander,James J. Gibbons,Robert T. Abraham,Semiramis Ayral‐Kaloustian,Tarek S. Mansour,Ker Yu	2009	93
9	Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796 Antimicrobial Agents and Chemotherapy ·Anita Y. M. Howe,Zita Kenzhegalieva,S V Johann,Emma R. Litvinenko,Srinivas K. Chunduru,Dorothy C. Young,Joel Bard,Rajiv Chopra,Girija Krishnamurthy,Tarek S. Mansour,Juliette O’Connell	2008	87
10	Naphthyl Tetronic Acids as Multi‐Target Inhibitors of Bacterial Peptidoglycan Biosynthesis ChemMedChem ·Tarek S. Mansour,Craig E. Caufield,Beth A. Rasmussen,Rajiv Chopra,Girija Krishnamurthy,健二奥野,Kristine Svenson,Joel Bard,Paula Danolić,Д. А. Дмитрович,Schuyler Antane,Youjun Yang,Anatoly Severin,Dominick Quagliato,Peter J. Petersen,Guy Singh	2007	38
11	Discovery of Proline Sulfonamides as Potent and Selective Hepatitis C Virus NS5b Polymerase Inhibitors. Evidence for a New NS5b Polymerase Binding Site Journal of Medicinal Chemistry ·Ariamala Gopalsamy,Rajiv Chopra,Robert D. Lambourne,Boris Dumenĉić,Mengxiao Shi,Kevin J. Curran,Seyyed Khatiboleslam Sadrnezhad,Kristine Svenson,Joel Bard,John W. Ellingboe,Atul Agarwal,Girija Krishnamurthy,Anita Y. M. Howe,Mark Orlowski,Boris Feld,Juliette O’Connell,Tarek S. Mansour	2006	46
12	Crystal Structure of the Toluene/o-Xylene Monooxygenase Hydroxylase from Pseudomonas stutzeri OX1 Journal of Biological Chemistry ·Matthew H. Sazinsky,Joel Bard,Alberto Di Donato,Stephen J. Lippard	2004	157
13	Identification, Characterization, and Crystal Structure ofBacillus subtilis Nicotinic Acid Mononucleotide Adenylyltransferase Journal of Biological Chemistry ·Andrea Olland,Kathryn Underwood,Robert Czerwiński,Mei-Chu Lo,Ann Aulabaugh,Joel Bard,Mark Stahl,W.S. Somers,Francis X. Sullivan,Rajiv Chopra	2002	49
14	Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin Nature ·Chester Lee Drum,Shui-Zhong Yan,Joel Bard,Yuequan Shen,Dan Lü,Sandriyana Soelaiman,Zenon Grabarek,Andrew Bohm,Wei‐Jen Tang	2002	317
15	Crystal Structure of an Ephrin Ectodomain Developmental Cell ·María Virginia Zudaire,Tyler Cutforth,Amy D. Gelinas,Alifia Iga Sutrisno,Joel Bard,Celia J. Harrison	2001	85
16	Single Channel Studies of Inward Rectifier Potassium Channel Regulation by Muscarinic Acetylcholine Receptors The Journal of General Physiology ·Joel Bard,Maya T. Kunkel,Ernest G. Peralta	2000	6
17	Structure of Yeast Poly(A) Polymerase Alone and in Complex with 3'-dATP Science ·Joel Bard,Alexander Zhelkovsky,Steffen Helmling,Thomas Earnest,Claire Moore,Andrew Bohm	2000	97

About Joel Bard

Joel Bard is a scholar working on Toxicology, Hepatology, Pharmacology, Physiology and Virology, having authored 17 papers that have together received 1.2k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (2 papers), Biochemical and Molecular Research (2 papers), PI3K/AKT/mTOR signaling in cancer (2 papers), Pharmacological Effects of Natural Compounds (2 papers), Hepatitis C virus research (2 papers), Monoclonal and Polyclonal Antibodies Research (2 papers), RNA Research and Splicing (2 papers) and RNA and protein synthesis mechanisms (2 papers). The work is most often cited by research in Hepatology (118 citations), Molecular Biology (768 citations), Inorganic Chemistry (124 citations), Biotechnology (52 citations) and Infectious Diseases (110 citations). Joel Bard has collaborated with scholars based in United States, Canada and Italy. Frequent co-authors include Andrew Bohm, Alberto Di Donato, Stephen J. Lippard, Matthew H. Sazinsky, Dan Lü, Shui-Zhong Yan, Yuequan Shen, Zenon Grabarek, Chester Lee Drum and Wei‐Jen Tang. Their work appears in journals such as Journal of Medicinal Chemistry, Journal of Biological Chemistry, Bioorganic & Medicinal Chemistry Letters, ACS Medicinal Chemistry Letters and CPT Pharmacometrics & Systems Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact